electroCore, Inc. (ECOR)

Kritische 8-K Meldungen

DatumMeldungSchwereFilingAuszug
06.09.2024Item 5.02 — Abgang SchlüsselpersonenHOCHSECge Act. ☐         Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain O
14.12.2023Item 5.02 — Abgang SchlüsselpersonenHOCHSEC        Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; C
09.08.2023Item 5.02 — Abgang SchlüsselpersonenHOCHSECcorporated by specific reference in such filing. Item 5.02. Departure of Directors or Certain Officers; Election of Dire
26.05.2023Item 5.02 — Abgang SchlüsselpersonenHOCHSEC☒         Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers;

Stammdaten

electroCore, Inc., a commercial stage medical device company, engages in the development and commercialization of a range of non-invasive vagus nerve stimulation (nVNS) therapies. The company is developing gammaCore, a prescription-only nVNS therapy for the acute treatment of pain associated with migraine and episodic cluster headache in adults. Its lead product is gammaCore Sapphire, a rechargeable and reloadable handheld device for regular or intermittent use over many years. The company was incorporated in 2005 and is headquartered in Rockaway, New Jersey.

Unternehmen & Branche

NameelectroCore, Inc.
TickerECOR
CIK0001560258
BoerseUS
SektorHealthcare
IndustrieMedical - Devices
SIC3845 · Electromedical & Electrotherapeutic Apparatus

Wertpapier & Kennzahlen

CUSIP
ISIN
TypCommon Stock
Marktkapitalisierung50,1 Mio. USD
Beta0,60
Dividendenrendite0,00 %

Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »

Finanzkennzahlen (SEC XBRL)

PeriodeFilingUmsatzNettoergebnisEPSAktivaEigenkapital
2025-12-3110-K32,032,000-13,966,000-1.6518,667,000-1,709,000
2025-09-3010-Q8,689,000-3,405,000-0.4021,412,000-1,073,000
2025-06-3010-Q7,381,000-3,671,000-0.4414,559,0001,113,000
2025-03-3110-Q6,719,000-3,855,000-0.4716,041,0004,365,000
2024-12-3110-K25,182,000-11,886,000-1.5920,471,0007,544,000
2024-09-3010-Q6,554,000-2,497,000-0.3121,045,0009,455,000
2024-06-3010-Q6,139,000-2,655,000-0.3822,355,00011,472,000
2024-03-3110-Q5,443,000-3,506,000-0.5313,890,0004,496,000
2023-12-3110-K16,030,000-18,834,000-3.4216,102,0007,442,000
2023-09-3010-Q4,508,000-4,032,000-0.6820,108,00011,040,000
2023-06-3010-Q3,551,000-4,903,000-1.0314,222,0007,064,000
2023-03-3110-Q2,780,000-5,867,000-1.2418,300,00011,847,000
2022-12-3110-K8,592,000-22,162,000-4.6924,756,00017,086,000
2022-09-3010-Q1,976,000-5,453,000-1.2029,491,00022,204,000
2022-06-3010-Q2,157,000-5,337,000-1.2033,481,00027,173,000
2022-03-3110-Q1,899,000-5,582,000-1.2037,181,00031,816,000
2021-12-3110-K5,451,000-17,218,070-4.3642,833,00036,648,000
2021-09-3010-Q1,487,000-3,993,00047,570,74940,480,750
2021-06-3010-Q1,269,000-2,894,00031,297,18323,980,896
2021-03-3110-Q1,204,000-5,384,00033,750,21926,031,814

Fondsaktivität (Vorquartalsvergleich)

Keine Fondsdaten für dieses Unternehmen vorhanden.

Insider-Transaktionen (12 Monate)

DatumInsiderRolleTypStückzahlKursWert (USD)ΔTrend
2026-04-10Goldberger Daniel SOpen Market Sale-16,0726.02-96,753.44-302,8%
2025-12-04Lev Joshua S.Officer, Chief Financial OfficerOpen Market Sale-2,5005.05-12,625.00-39,5%
2025-12-02Goldberger Daniel SDirector, Officer, Chief Executive OfficerOpen Market Purchase1,0004.844,840.00+15,1%
2025-11-12Lev Joshua S.Officer, Chief Financial OfficerOpen Market Sale-2,1666.18-13,385.88-41,9%
2025-08-11Errico Thomas J.DirectorOpen Market Purchase15,0004.4767,050.00+209,8%
2025-08-11Goldberger Daniel SDirector, Officer, Chief Executive OfficerOpen Market Purchase1,0004.234,230.00+13,2%
2025-05-23GANDOLFO JOHN PDirectorOpen Market Purchase1,8005.019,018.00+28,2%
2025-05-12Errico Thomas J.DirectorOpen Market Purchase10,0004.7747,735.00+149,4%

Top-Fondshalter

Keine Fondsdaten zu dieser Aktie vorhanden.

Hinweis

Erweitert ×